Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.
复制标题
多发性硬化症患者 COVID-19 和疾病缓解疗法的经验：对 873 个已发表病例的回顾。
DOI：
10.3390/jcm9124067
复制
发表时间：
2020-12-16
影响因子：
3.9
通讯作者：
Skripuletz T
中科院分区：
文献类型：
--
作者：
Möhn N;Konen FF;Pul R;Kleinschnitz C;Prüss H;Witte T;Stangel M;Skripuletz T
严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 大流行对医疗保健系统的所有参与者来说都是一个挑战。在大流行开始时，许多医生问自己，他们的患者，特别是那些患有慢性病的患者，面临着哪些风险。我们概述了迄今为止文献中发表的所有多发性硬化症 (MS) 和 SARS-CoV-2 感染患者。总共有 873 名 SARS-CoV-2 阳性多发性硬化症患者的出版物，并且可以提供 700 名患者的结果信息。关于不同的疾病修饰疗法 (DMT)，到目前为止，大多数病例是在抗 CD20 治疗下描述的 (n = 317)。所有 MS 患者的死亡率为 4%，另外 3% 需要有创或无创通气。在观察严重和致命病例时，特别值得注意的是，未接受 DMT、既往患有心血管疾病或患有严重残疾的患者面临风险。免疫抑制治疗本身似乎并不是一个重要的危险因素。相反，可以合理地假设这些疗法可以通过减轻细胞因子风暴直接发挥保护作用，或者通过降低多发性硬化症的疾病活动间接发挥保护作用。
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a challenge for all participants in the healthcare system. At the beginning of the pandemic, many physicians asked themselves what risk their patients, especially those with chronic diseases, were exposed to. We present an overview of all patients with multiple sclerosis (MS) and SARS-CoV-2 infection published in the literature so far. In total, there are publications on 873 SARS-CoV-2 positive MS patients and information on the outcome can be given for 700 patients. With regard to the different disease modifying therapies (DMTs), by far the most cases were described under anti-CD20 treatment (n = 317). The mortality rate of all MS patients was 4% and a further 3% required invasive or non-invasive ventilation. When looking at the severe and fatal cases, it is particularly noticeable that patients without DMTs, with previous cardiovascular diseases, or with a severe degree of disability are at risk. Immunosuppressive therapy itself does not appear to be a substantial risk factor. Rather, it is reasonable to assume that the therapies could be protective, either directly, by mitigating the cytokine storm, or indirectly, by reducing the disease activity of MS.
登录
查看更多内容
影响因子：
5.8
作者：
Dersch, Rick;Wehrum, Thomas;Berger, Benjamin
通讯作者：
Berger, Benjamin
影响因子：
3.3
作者：
Ciardi, Maria Rosa;Zingaropoli, Maria Antonella;Mastroianni, Claudio Maria
通讯作者：
Mastroianni, Claudio Maria
影响因子：
4
作者：
Foerch, Christian;Friedauer, Lucie;Adam, Elisabeth H.
通讯作者：
Adam, Elisabeth H.
DOI：
10.1007/s42399-020-00369-y
发表时间：
2020-01-01
期刊：
SN comprehensive clinical medicine
影响因子：
--
作者：
Arca, Karissa N;Starling, Amaal J
通讯作者：
Starling, Amaal J
影响因子：
4
作者：
Celius EG
通讯作者：
Celius EG